Rivaroxaban Oral Tablet [Xarelto]
Approved
Rivaroxaban Oral Tablet [Xarelto] is one of 6 therapeutic programs targeting Kawasaki Disease. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
5 competitors in Kawasaki Disease
#DrugCompanyPhaseTrials
1Coumadin
AAbbott
Approved
Aspirin or Clopidogrel
SSunnybrook Health Sciences Centre
Approved
Rivaroxaban Oral Tablet [Xarelto]
CChildren's Hospital of Fudan University
Approved
Bayer Aspirin
BayerPreclinical
Ivig
ArgenxPreclinical
Firsekibart
RRuijin Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Approved[1]